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Abstract
Objectives. To examine incidence of treatment changes due to abnormal blood-test results and, to explore rates
of treatment changes due to liver, kidney and haematological blood-test abnormalities in autoimmune rheumatic
diseases (AIRD) treated with low-dose MTX or LEF.
Methods. Data for people with AIRDs prescribed MTX or LEF were extracted from the Clinical Practice Research Datalink.
Participants were followed-up from first prescription of MTX or LEF in primary care. Primary outcome of interest was drug
discontinuation, defined as a prescription gap of 90 days following an abnormal (or severely abnormal) blood-test result.
Dose reduction was examined between consecutive prescriptions. Incidence rates per 1000 person-years were calculated.
Results. 15, 670 and 2,689 participants contributing 46, 571 and 4,558 person-years follow-up were included in MTX
and LEF cohorts, respectively. The incidence of MTX and LEF discontinuation with abnormal (severely abnormal) blood-
test was 42.24 (6.16) and 106.53 (9.42)/1000 person-years in year 1, and 22.44 (2.84) and 31.69 (4.40)/1000 person
years, respectively, thereafter. The cumulative incidence of MTX and LEF discontinuation with abnormal (severely abnor-
mal) blood tests was 1 in 24 (1 in 169), 1 in 9 (1 in 106) at 1 year; and 1 in 45 (1 in 352), 1 in 32 (1 in 227) per-year,
respectively, thereafter. Raised liver enzymes were the commonest abnormality associated with drug discontinuation.
MTX and LEF dose reduction incidence were comparable in year 1, however, thereafter MTX dose was reduced more
often than LEF [16.60 (95% CI 13.05, 21.13) vs 8.10 (95% CI 4.97, 13.20)/1000 person-years].
Conclusion. MTX and LEF were discontinued for blood-test abnormalities after year 1 of treatment, however, dis-
continuations for severely abnormal results were uncommon.
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Introduction
Autoimmune rheumatic diseases (AIRDs) affect >1%
adults and are treated with DMARDs [1–5]. These drugs
can cause cytopenia, raised liver enzymes and AKI and,
fortnightly to monthly monitoring blood-tests are recom-
mended when initiating treatment with less frequent
testing thereafter [6]. In the UK, DMARDs are initiated in
a rheumatology clinic with prescriptions dispensed from
the hospital and fortnightly blood monitoring overseen
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. Treatment discontinuation and dose reductions were more common in the first year of treatment and occurred
at a stable but lower rate thereafter.
. Severely abnormal blood-test results were uncommonly associated with methotrexate and leflunomide discontinuations.
. Elevated liver enzymes were the commonest reason for discontinuing methotrexate and leflunomide.
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by the rheumatology team. Once an effective, tolerated
and stable dose is reached, the responsibility for pre-
scribing and arranging 2–3 monthly blood-tests is
handed to the GP under shared-care policy supported
by the British Society for Rheumatology (BSR) and
Royal College of General Practitioners [6]. The
Rheumatology team is contacted if there are side-
effects, including blood-test abnormalities and oversee
treatment changes. Monitoring blood-tests are discon-
tinued after 2 years for SSZ while long-term testing is
continued for low-dose MTX and LEF [6, 7]. Whether
such long-term testing influences the decision to discon-
tinue treatment is not known because most clinical trials
are shorter than 1 year, and many observational studies
report cumulative toxicity including outcomes from the
treatment initiation phase during which reversible drug-
induced target organ injury is common [8–10]. However,
evidence from a large 2-year clinical trial suggests that
DMARD discontinuation due to target organ damage
becomes less common with increasing duration of treat-
ment [10]. With growing use of DMARDs and the corre-
sponding increased burden and cost of testing, it is
important to evaluate the benefit from regular monitoring
blood-tests for long-term low-dose MTX or LEF treat-
ment [11]. Thus, the objectives of this study were to
examine the incidence of drug discontinuation and dose
reduction with abnormal blood-test results in AIRDs
treated with long-term low-dose MTX or LEF. We also
explored the data to examine whether the incidence of
MTX discontinuation due to any abnormal blood-test re-
sult, elevated liver enzymes, AKI or cytopenia differed in
RA and PsA as there is evidence that psoriasis
increases the risk of hepatotoxicity from MTX [12, 13].
Methods
Data source
Data from Clinical Practice Research Datalink (CPRD)
Gold was used. Incepted in 1987, CPRD-Gold is a longi-
tudinal anonymized electronic database of health
records from over 19 million participants in 927 general
practice surgeries across the UK and covers 4.52% of
UK residents currently. CPRD participants are represen-
tative of the UK population in terms of age, sex and eth-
nicity [14]. CPRD includes information on demographic
details, lifestyle factors (e.g. smoking, alcohol intake),
diagnoses, results of investigations including blood tests
and physical examination and details of all primary-care
prescriptions [14]. Diagnostic and prescription data are
recorded as Read codes and product codes, respect-
ively. Blood-test results are stored as numeric values.
Additionally, general practitioners (GPs) may record ab-
normal blood-test results using Read codes.
Approvals
Independent Scientific Advisory Committee of the
MHRA (Reference: 19_275R).
Study design
Cohort study: Two separate cohorts were constructed
comprising of participants prescribed MTX and LEF,
respectively.
Study duration: 1 January 2007 to 31 December 2019
The study began on 1 January 2007 as the BSR guide-
lines recommending aggressive treatment of RA and
shared-care monitoring of DMARDs were published in
2006 [4, 15].
Inclusion criteria
Participants were required to meet the following criteria:
. diagnosed with either RA, SLE, PsA, ReA, AS, IBD
associated arthritis, GCA, PMR or CTDs at age 18
years, within the study period;
. 1 GP prescription of MTX (oral or subcutaneous) or
LEF after the first record of AIRD diagnosis in CPRD
and
. continuous registration for 1 year before the first AIRD
diagnosis date in a GP practice contributing research
quality data to CPRD.
The latter two criteria prevents prevalent AIRD cases
on long-term DMARDs that have recently changed GP
surgeries from entering the cohort as incident cases.
Exclusion criteria
Chronic liver disease (autoimmune hepatitis, primary
sclerosing cholangitis, hepatitis B or C, cirrhosis); haem-
atological malignancies (lymphoma, leukaemia); myelo-
dysplasia; haemolytic anaemia, neutropenia, idiopathic
thrombocytopenic purpura or chronic kidney disease
(CKD) stage 4 prior to cohort entry.
Cohort entry
First shared-care GP prescription of MTX or LEF,
respectively.
Cohort exit
The earliest of date of outcome, death, transfer out of
the GP practice, last data collection from the GP prac-
tice, or 31 December 2019. For the dose reduction ana-
lysis, follow-up was censored on the first prescription
date at which dose data were missing.
Outcomes
1. Drug discontinuation with abnormal blood-test result:
Prescription gap of 90 days, with an abnormal
blood-test result or Read code indicating abnormal
blood-test result within 660 days of the date of last
prescription. The thresholds for abnormal blood-test
results were: white blood cells (WBCs) <3.5  109/l;
neutrophils <1.6  109/l; platelets <140  109/l; ALT/
AST >100 IU/l (6); and kidney function decline defined
as either CKD progression based on Read codes
entered by the GP using Kidney Disease Improving
Global Outcomes (KDIGO) CKD guidelines [16], or a
creatinine increase of >26 lmol/l, the threshold for
consideration of AKI [17].
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2. Drug discontinuation with severe abnormal blood-test
result: Prescription gap of 90 days, with severely ab-
normal monitoring blood-test result within 660 days
of the date of last prescription. Severe blood-test
abnormalities were defined as: WBCs <2.5  109/l;
neutrophils <1.0  109/l; platelets <50  109/l; ALT or
AST >200 IU/l or serum creatinine >2 times the previ-
ous value. These thresholds were selected as they re-
flect grade-3 cytopenia according to Common
Terminology Criteria for Adverse Events, stage 2 acute
kidney injury according to the KDIGO guidelines and
meet the criteria for drug induced liver injury with ALT
or AST >5 times upper limit of normal [17–19].
3. Dose reduction with abnormal, and severely abnormal
blood-test result: Dose reduction between two con-
secutive prescriptions.
4. Drug discontinuation (any reason): Gap of 90 days
between the last prescription date and the earliest of
date of death, transfer out of the GP practice, last
data collection from GP practice or 31 December
2019.
Data management
Read code and product code lists were developed to
ascertain AIRDs, inclusion and exclusion criteria, pre-
scriptions and outcomes (available on request).
Outcome validation
A random sample (40%) of MTX discontinuations with a
blood-test abnormality was drawn. Data for all consulta-
tions within 660days of the abnormal blood-test result
was extracted. A.A. (Consultant Rheumatologist trained in
General Medicine and Rheumatology) screened all Read
codes to exclude administrative codes e.g. reminder letter
sent, telephone appointment, etc. All clinical experts in
the study team [two rheumatologists, one nephrologist,
one hepatologist, one gastroenterologist, one haematolo-
gist (C.F.) and one academic GP] reviewed the remaining
Read codes. Each expert could vote in any condition if
they felt that the condition, its treatment or its complica-
tions could cause blood, liver or kidney injury. The final
list was reviewed by all clinicians and four Read codes
were excluded as they were non-specific or could imply
DMARD side effects if used alone (Supplementary Table
S1, available at Rheumatology online).
Statistical analyses
Mean (S.D.) and n (%) were used for descriptive pur-
poses. The proportion of MTX discontinuations with
blood test abnormality that could potentially be
explained by an underlying illness was determined.
Survival analysis was undertaken to calculate the inci-
dence of outcomes [95% confidence intervals (CIs)] per
1000 person-years for entire follow-up period, first 12
months of follow-up and the subsequent period.
Incidence of drug discontinuation or dose reduction with
individual blood-test abnormalities were calculated.
Missing data on doses were not imputed as they were
missing not at random and imputation could create
spurious outcomes. Life tables were constructed to
estimate the cumulative incidence at 1- and 5-year fol-
low-up. Cumulative hazards were plotted using Nelson-
Aalen graphs.
Sensitivity analysis
The incidence of MTX discontinuation for blood-test
abnormalities was examined in a sensitivity analysis
after excluding cases with SLE and other CTDs as these
conditions can cause cytopenia. The incidence of MTX
discontinuation with abnormal blood-test results was
calculated separately for RA and PsA. Data manage-
ment and analysis were performed in Stata v16.
Results
Data for 24 871 and 3897 participants with AIRDs pre-
scribed MTX and LEF were ascertained. Of these,
15 670 and 2689 participants contributing 46 571 and
4558 person-years follow-up were included in the MTX
and LEF cohorts, respectively (Supplementary Figs S1
and S2). The median (IQR) MTX and LEF dose at cohort
entry was 10 (7.5–15) mg/week and 10 (10–20) mg/day,
respectively. 2.1% participants were prescribed both
drugs at cohort entry or within the first 6 months. The
majority of participants in the MTX cohort had RA
(65.8%), were female (64.6%) and their mean (S.D.) age
was 57 (15) years. In the LEF cohort, 63.9% had RA,
67.3% were female and the mean (S.D.) age was 57 (13)
years (Table 1). The median (IQR) follow-up in the MTX
and LEF cohorts was 2.31 (0.82–4.92) and 1.03 (0.33–
2.94) years, and there were 1262 and 259 drug discon-
tinuations due to abnormal monitoring blood test results,
respectively. Of these 95.6 and 95% were ascertained
using values of blood-test results while the remainder
were ascertained using Read codes. The 40% random
sample of MTX discontinuations with blood-test abnor-
malities consisted of 505 cases and yielded 27 (5.35%)
discontinuations that could potentially be explained by
another underlying illness or its treatment or
complications.
The incidence of MTX and LEF discontinuation for any
reason, with any blood-test abnormality, and with any
severe blood-test abnormality was highest in the first 12-
months of shared-care prescribing (Table 2 and Fig. 1).
The cumulative annual incidence of discontinuing MTX
with abnormal, and severely abnormal blood-test results
was 1 in 24 and 1 in 169 at 1 year, and this reduced to
1 in 45 and 1 in 352 per-year, respectively, thereafter.
Similarly, for LEF, the cumulative annual incidence of dis-
continuing treatment with abnormal and severely abnor-
mal blood-test results was 1 in 9 and 1 in 106 at 1 year,
reducing to 1 in 32 and 1 in 227 per-year, respectively,
thereafter. The proportion discontinuing MTX with abnor-
mal blood test results was lower than that of LEF at 1-
year and 5-year follow-up, being 4.2% (95% CI 3.7,
4.4%) for MTX vs 9.3% (8.1, 10.7%) for LEF at 1 year,
and 12.2% (11.5, 12.9%) for MTX vs 20.5% (17.8,










atology/keab254/6174126 by guest on 23 August 2021
available at Rheumatology online). However, the cumula-
tive incidence of MTX and LEF discontinuation with se-
vere blood-test abnormalities were comparable at both
time points.
The incidence of MTX discontinuation with raised liver
enzymes, and decline in kidney function was higher in
the first 12 months than subsequently, whereas the inci-
dence of MTX discontinuation with cytopenia remained
stable throughout (Table 3 and Fig. 2; Supplementary
Fig. S4, available at Rheumatology online). On the con-
trary, the incidence of LEF discontinuation with cytope-
nia, elevated liver enzymes, and kidney function decline
was higher in the first 12 months (Table 3 and Fig. 2).
LEF discontinuation with severe individual blood-test
abnormalities was numerically more common in the first
12 months than subsequently (Table 3).
Sensitivity analysis
On excluding people with SLE or CTDs, the incidence
(95% CI) of MTX discontinuation was 27.40 (25.90,
28.98)/1000 person-years for any blood-test abnormality
and, 5.88 (5.21, 6.63)/1000 person-years for leucopenia,
4.40 (3.83, 5.05)/1000 person-years for neutropenia and
5.75 (5.09, 6.49)/1000 person-years for thrombocyto-
penia. This was comparable to that observed in the en-
tire dataset (Table 2). There were no differences when
the analyses were stratified for duration of follow-up
(data not shown).
The incidence of MTX discontinuation due to elevated
liver enzymes was higher in psoriatic arthritis than RA.
This difference was present both early and late in the
treatment course and for any or severely elevated liver
enzymes. However, the incidence of MTX discontinu-
ation due to cytopenia or renal function decline was
comparable in the two populations (Table S2).
Dose reduction
85.3% and 30% participants in the MTX and LEF
cohorts had at least one dose data missing, and their
follow-up was censored at this time point. MTX dose
was reduced more often with abnormal blood-test
results than LEF after the first 12 months (Table 4).
However, the cumulative incidence of dose-reduction
with any blood test abnormality and with severe blood-
test abnormalities were comparable for MTX and LEF at
FIG. 1 Nelson–Aalen cumulative hazard estimates for MTX and LEF discontinuation due to: any reason (A), any abnor-
mal blood-test results (B), any severely abnormal blood-test results (C).
TABLE 1 Baseline characteristics of participants in the
MTX (n¼ 15 670) and LEF (n¼2,689) cohorts
Characteristics MTX LEF
Age at cohort entry, mean (S.D.) 57.2 (14.8) 57 (13.4)
Female, n (%) 10 115 (64.6) 1807 (67.3)
Smoking status, n (%)
Non-smoker 7339 (46.8) 1221 (45.5)
Current smoker 3300 (21.1) 555 (20.7)
Ex-smoker 4972 (31.7) 902 (33.6)
Missing 59 (0.4) 8 (0.3)
Alcohol use, n (%)
Non-user 3132 (20) 606 (22.6)
Low 8714 (55.6) 1452 (54.1)
Medium 573 (3.7) 80 (3.0)
Hazardous 875 (5.6) 140 (5.2)
EX-user 563 (3.6) 149 (5.6)
Missing 1813 (11.6) 259 (9.6)
AIRD type, n (%)
RA 10 306 (65.8) 1715 (63.9)
Lupus/other CTD 468 (3.0) 26 (1.0)
PMR/GCA 1597 (10.2) 203 (7.6)
Spondyloarthropathy 3299 (21.1) 742 (27.6)
Other DMARDs, n (%)
LEF 331 (2.1) /
MTX / 57 (2.1)
SSZ 2660 (17.0) 395 (14.7)
/: value <5. Alcohol and smoking status were derived
from categorical data in CPRD Additional Clinical file.
Alcohol consumption was classified as low (1-14 units/
week), medium (15-21 units/week) and hazardous (>21
units/week).
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1 and 5 years. (Supplementary Fig. S3, available at
Rheumatology online). On evaluating individual blood-
test abnormalities, LEF dose was more likely to be
reduced with neutropenia than MTX, and less likely to
be reduced with abnormal LFTs (Table 4).
Seven participants prescribed MTX had dose reduction
for severely abnormal blood-test results with incidence of
1.03 (0.49, 2.16) per 1000 person-years. Fewer than five
participants prescribed LEF had dose reduction for se-
verely abnormal blood-test results during shared care
prescribing. Due to office for national statistics and
CPRD policy to avoid accidental identification, we are un-
able to present incidence for outcomes with <5 events.
Discussion
This is the largest study to examine the incidence of
treatment changes with abnormal blood-test results dur-
ing long-term MTX or LEF therapy. In comparison, the
largest systematic review (SR) of low-dose MTX
included data on liver and bone-marrow toxicity from
3806 and 3463 participants from 29 studies, and the
previous largest study of LEF included data for 3325
participants [9, 20].
This study focused on patients successfully initiated
on long-term DMARDs as there is lack of data on bene-
fit from monitoring during this period [6]. It reports that
treatment changes with abnormal blood-test results are
common in the first 12 months after hospital-supervised
treatment initiation and stabilization, and becomes less
frequent thereafter. Treatment changes with severe
blood-test abnormalities were uncommon and became
less frequent over time.
Our observation that 3.3% participants discontinued
low-dose MTX with elevated liver enzymes are compar-
able to the 3.7% incidence reported in the SR [9], and,
are higher than those in the CORRONA registry [12]. In
our study, 2.8% participants discontinued MTX with
cytopenia. This is lower than the 6.7% cumulative inci-
dence of cytopenia during MTX therapy in the SR [9].
The incidence of MTX discontinuation with leucopenia
(0.6% vs 1.2%) and neutropenia (0.5% vs 1.8%) at 1
year was lower than the cumulative incidence reported
in a recent SR of clinical trials that included events from
the treatment initiation phase [21]. This may be due to
the fact that our outcome definition required drug dis-
continuation with cytopenia, whereas the SRs reported
on the incidence of any cytopenia, including those not
requiring treatment discontinuation [9, 21].
Solomon et al. [22] reported a lower cumulative inci-
dence of elevated liver enzymes (0.56%) and haemato-
logical abnormalities (0.95%) using data from a 3-year
trial of low-dose MTX for preventing cardiovascular
events in a population without AIRD. The lower inci-
dence may be due to non-prescription of other
DMARDs and less NSAID use [22].
As reported previously, raised liver enzymes were the
commonest abnormality associated with MTX discon-
tinuation, and the risk reduced after 12 months [9, 10,
22–24]. On the contrary, the incidence of MTX discon-
tinuation with cytopenia was similar throughout the
treatment period. Previous 2-year trials of MTX have
reported cytopenia only occasionally, and unrelated to
treatment duration [10, 23].
The cumulative incidence of LEF discontinuation with
elevated liver enzymes (3.0% vs 3.1%), and with either
cytopenia or elevated liver enzymes (7.7% vs 7.0%)
were comparable to previous reports [12, 20]. As
reported previously, there was a higher incidence of LEF
discontinuation with blood-test abnormalities in the first
12 months [10].
LEF was more likely to be discontinued with abnormal
blood-tests than MTX. These findings are contrary to the















Ever 3584 46 571 76.96 (74.48, 79.52) 946 4,558 207.54 (194.73, 221.20)
First 12 months 2185 12 327 177.25 (169.97, 184.84) 765 1,593 480.10 (447.26, 515.36)
After 12 months 1399 34 244 40.85 (38.81, 43.00) 181 2,965 61.05 (53.01, 70.30)
With any blood-test
abnormality
Ever 1262 45 435 27.78 (26.29-29.35) 259 4,449 58.22 (51.55, 65.76)
First 12 months 517 12 239 42.24 (38.75, 46.05) 168 1,577 106.53 (91.58, 123.92)
After 12 months 745 33 196 22.44 (20.90, 24.09) 91 2,872 31.69 (25.89, 38.79)
With severe blood-test
abnormality
Ever 170 46 466 3.66 (3.15, 4.25) 28 4,548 6.16 (4.25, 8.92)
First 12 months 73 12 317 5.93 (4.71, 7.45) 15 1,592 9.42 (5.68, 15.63)
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results of a trial in which folate supplementation was not
mandatory for participants randomized to MTX [10].
However, in another trial where folate supplementation
was mandatory for participants randomized to MTX
there were more LEF than MTX discontinuations for ele-
vated liver enzymes (7.7% vs 4.4%) [25]. Folic acid sup-
plementation was recommended in the BSR guidelines
and became common practice in the early 2000s, and
our findings of greater liver toxicity with LEF are
expected.
MTX and LEF discontinuation with kidney function de-
cline was uncommon, though more frequent in the first
12 months, raising the possibility that these drugs may
be nephrotoxic. However, published data suggests that
nephrotoxicity is uncommon with these drugs. Only one
case of reversible kidney failure due to MTX was
reported in a clinical trial, and there is one case report
of LEF induced interstitial nephritis but this was associ-
ated with chronic over-dosing and with no cases of LEF
nephrotoxicity reported in clinical trials [10, 25–28]. The
largest clinical trial to examine the side-effects from low-
dose MTX albeit in a non-AIRD population reported an
average 1.9 ml/min/1.73 m2 improvement in estimated
glomerular filtration rate, and 15% lower risk of renal ad-
verse events compared with placebo [22]. A previous 2-
year clinical trial reported no change in creatinine with
LEF, and only a marginal increase in creatinine with
MTX [10]. These findings suggest that there is low risk
of nephrotoxicity with LEF and low-dose MTX.
MTX was twice as likely to be discontinued with ele-
vated liver enzymes in PsA than in RA, as reported pre-
viously [12, 13]. However, the rates of MTX
discontinuation due to cytopenia and renal function de-
cline were comparable suggesting this risk is target-
organ specific. Further research is required to under-
stand the underlying mechanism. However, these find-
ings suggest that PsA patients treated with MTX should
be monitored carefully for hepatotoxicity and advised to
minimize risk factors for the latter.
Most treatment discontinuations in this study were not
due to abnormal blood-test results. The cumulative inci-
dence of all-cause MTX and LEF discontinuation at 1-
and 5 years in this study were comparable to previous
reports [29–31]. Given a wide MTX dosing range, dose
reduction was more common for MTX than for LEF.
Strengths of this study include large sample size allow-
ing us to provide precise estimates for anticipated low
event rates. Additionally, this study used real-world data,
thus increasing generalizability. Outcomes were stratified
according to their severity and time-course to add granu-
larity to the results and increase clinical utility. Data from
the period when MTX or LEF was commenced were
excluded by design and the results are applicable to
long-term maintenance treatment where the greatest bur-
den of testing lies. Although this may be viewed as a
limitation, it does not reduce the validity of our findings.
Missing outcome data is a concern with studies using
consultation-based databases. However, the cumulative
estimates of drug discontinuation reported in this study
are consistent with those from previous trials and obser-
vational studies. Additionally, our validation exercise
revealed that only 5% outcomes were potentially related
to another condition, its complication or its treatment.
We used a parsimonious list of conditions in this exercise
FIG. 2 Nelson–Aalen cumulative hazard estimates for drug discontinuation due to the individual abnormal blood-test
results: MTX discontinuation due to mild abnormal blood-test results (A), severely abnormal blood-test results (C);
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including those for which there was only a remote possi-
bility of abnormal blood-test results.
However, this study has several limitations. First, our
findings are not applicable to patients at very high risk
of drug toxicity and not transferred to shared-care pre-
scribing e.g. CKD-4, pre-existing chronic liver disease.
However, it is extremely uncommon to offer MTX or LEF
to such patients, and the results of our study will there-
fore apply to the vast majority of AIRD patients.
Secondly, dose data were missing for the majority of
MTX and a large proportion of LEF prescriptions. This
limits the validity of dose-reduction analysis. Thirdly,
CKD progression and a serum creatinine increase of
>26 lm/l, the minimum change required to consider the
presence of AKI, was used to ascertain drug discontinu-
ation with kidney function decline [17]. The guideline
specifies that the increase in creatinine should occur
within 48 h. We were unable to meet this part of the def-
inition due to inherent large gaps between blood-tests,
potentially resulting in an overestimate of the incidence
of AKI. Our results therefore represent a worst-case
scenario with respect to impact on kidney function.
Some of the abnormal blood-test results could be due
to concurrent prescription of other DMARDs e.g. SSZ.
This can potentially elevate the outcome event rate.
However, this is unlikely to play a large part as our out-
come definition required a prescription gap of at-least
90 days and, it can reasonably be expected that in this
period most rheumatologists will be able to ascertain
the actual drug responsible for the blood-test abnormal-
ity. Moreover, some patients prescribed first-line sub-
cutaneous MTX for RA from the hospital clinic, and
stepping down to GP prescribed and monitored oral
MTX may appear as incident users of MTX. However,
this is likely to be uncommon as most patients with RA
in the UK are commenced on oral MTX first-line and, if
commenced on subcutaneous MTX first-line may have a
contraindication to oral therapy. Research suggests that
patients prescribed subcutaneous MTX change to the
oral route in <3% instances [32]. Additionally, some
treatment discontinuations in people with SLE may be
due to increased disease activity e.g. cytopenia resulting
in treatment escalation. However, a sensitivity analysis
excluding cases with SLE or CTD reported similar event
rates as the main analysis. Finally, it is difficult to attri-
bute causality for adverse events and some potential
adverse events may be unrelated to the treatment.
MTX and LEF are uncommonly discontinued for
blood-test abnormalities after the first year of shared-
care prescription and discontinuations for severely ab-
normal blood-test results are even less frequent. These
data will be useful when counselling patients in routine
clinical practice. Elevated liver enzymes were the com-
monest blood-test abnormality to cause treatment dis-
continuations. This underlines the need to advise
patients treated with DMARDs to minimize other risk-
factors for hepatotoxicity. Further research is required to
identify risk-factors of target-organ damage, and, to de-
velop a prognostic model for risk-stratified blood-test
monitoring. This is being evaluated by our team in an-
other ongoing study that will also assess the acceptabil-
ity and cost-effectiveness of risk-based monitoring.
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